Back to News
Market Impact: 0.2
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Source: zacks.com
Analyst InsightsCompany Fundamentals
Silence Therapeutics (SLN) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The article provides no earnings figures or share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
SLN0.45
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Wells Fargo CFO on Earnings, Deals, Consumer Strength
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future